FDA Approves Nuvalent's Jideytro (zidesamtinib) for ROS1-Positive NSCLC
On July 22, 2026, the U.S. Food and Drug Administration (FDA) approved Nuvalent's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 kinase inhibitor.
The regulatory clearance occurred approximately two months ahead of its projected schedule, representing a major milestone for Nuvalent and a significant advancement in the targeted oncology landscape.
A Next-Generation, ROS1-Selective TKI
ROS1-positive NSCLC accounts for approximately 1% to 2% of all non-small cell lung cancer cases, occurring predominantly in younger, non-smoking patients. While first-generation ROS1 inhibitors (such as crizotinib and entrectinib) are initially effective, patients almost inevitably develop resistance mutations—most notably the solvent front mutation ROS1 G2032R—and brain metastases.
Jideytro is a next-generation, ROS1-selective tyrosine kinase inhibitor (TKI) designed specifically to:
- Overcome Resistance: Show potent activity against wild-type ROS1 as well as resistant mutations, including the G2032R solvent front mutation.
- Brain Penetrance: Demonstrate high central nervous system (CNS) activity to treat and prevent brain metastases.
- Selectivity: Selectively inhibit ROS1 over the structurally similar TRK (tropomyosin receptor kinase) family, avoiding the severe off-target neurological toxicities (such as dizziness, ataxia, and weight gain) commonly associated with dual TRK/ROS1 inhibitors.
The clinical profile of zidesamtinib was supported by robust safety and efficacy data, showing significant, durable tumor shrinkage and prolonged progression-free survival in heavily pretreated patients, including those with active brain metastases and those who had failed prior ROS1 TKI therapies.
Market Context and Next Steps
The approval positions Nuvalent to compete directly in the ROS1-positive NSCLC market. The company is actively preparing for the commercial launch of Jideytro in the United States. Furthermore, Nuvalent is advancing a robust pipeline of other selective kinase inhibitors, including NVL-655 (a selective ALK inhibitor) which is also under active clinical development.
"The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected..." — FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout